L-Clausenamide

Clausenamide is a small chiral molecule (a gamma-lactam / pyrrolidinone) first obtained from Clausena lansium, a plant used in traditional Chinese medicine. Because the molecule has several chiral centers, many enantiomers exist; systematic synthesis and testing at the Institute of Materia Medica of the Chinese Academy of Medical Sciences established the (-)-enantiomer as the eutomer, or active form, for cognitive enhancement, with the (+)-enantiomer largely inactive ^[1].

Mechanistically, (-)-clausenamide is described as a genuinely multi-target nootropic: it mildly elevates intracellular calcium, modulates the cholinergic system, regulates synaptic plasticity and long-term potentiation, and switches on cellular signaling pathways tied to learning and memory ^[1]. It also carries a strong neuroprotective and antioxidant character. In primary cortical neurons it blunts oxygen-glucose-deprivation injury by inhibiting endoplasmic-reticulum stress and apoptosis ^[2]; it protects neurons against okadaic-acid and beta-amyloid toxicity while improving learning in ovariectomized rats ^[4]; and it prevents ferroptotic death of dopaminergic neurons by interacting with 5-lipoxygenase (ALOX5), improving behavior in a Parkinson's disease model ^[3].

The compound is supplied as a research powder. It is best understood as an extensively studied preclinical anti-dementia and neuroprotection candidate, not an approved drug.

Clausenamide comes from an edible plant and has been studied fairly extensively in Chinese preclinical work without major toxicity signals reported, but there are no published human clinical safety trials, so its side-effect and interaction profile in people is not established. As a compound that modulates calcium, cholinergic tone and lipoxygenase signaling, theoretical interactions with cholinergic drugs or other neuroactive agents cannot be ruled out. It should be regarded as a research chemical rather than a proven supplement; the encouraging preclinical safety picture does not substitute for human data.

Clausenamide was isolated from Clausena lansium (wampee), a fruit tree used in traditional Chinese medicine, and was developed as a nootropic lead principally at the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, with Zhang Juntian and colleagues driving much of the enantioselective synthesis and pharmacology over several decades ^[1][4]. It stands as one of China's notable home-grown anti-dementia drug candidates.

In the neuropharmacology literature (-)-clausenamide is well regarded as a thoroughly studied natural-product nootropic with a coherent multi-target mechanism and reproducible neuroprotective data across ischemia, Alzheimer and Parkinson models ^[1][2][3]. In the nootropic community it is relatively obscure and hard to source, and the honest caveat is that despite a strong preclinical dossier it has not been validated in human trials, so its real cognitive benefit in people remains unproven.